Different antihyperglycaemic drug effects on glycaemic variability in Type 2 diabetic patients

Código QR

Different antihyperglycaemic drug effects on glycaemic variability in Type 2 diabetic patients

Optimizing treatments for type 2 diabetes mellitus (T2DM) remains an urgent issue. In addition to T2DM treatment strategies, such as glycaemic goals (glucose and glycated haemoglobin ? HbА1c) among different patient populations, the influence of glycaemic variability (GV) on the prognosis of patient...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Alina Babenko, Elena Ivanovna Krasilnikova, Nikolay Pavlovich Likhonosov, Anna Pavlovna Likhonosova, Elena Nikolaevna Grineva
Formato:	article
Lenguaje:	EN RU
Publicado:	Endocrinology Research Centre 2014
Materias:	continuous glucose monitoring glycaemic variability incretins glp-1 analogues/mimetics dpp-4 inhibitors Nutritional diseases. Deficiency diseases RC620-627
Acceso en línea:	https://doaj.org/article/eff73a7fd76a4619b9da53893fae77f0
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Glycaemic variability in diabetes: a tool for assessing the quality of glycaemic control and the risk of complications
por: Vadim Valer'evich Klimontov, et al.
Publicado: (2014)

Modern antihyperglycemic agents prescribed in Russia for type 2 diabetes mellitus
por: Yury Ivanovich Suntsov
Publicado: (2012)

Efficacy of Glucagon-Like Peptide-1 Analogs in Nonalcoholic Fatty Liver Disease: A Systematic Review
por: Teshome G, et al.
Publicado: (2020)

Role of incretin based therapies in the treatment of diabetic kidney disease
por: Paola Fioretto, et al.
Publicado: (2018)

Clinical Inertia and 2-Year Glycaemic Trajectories in Patients with Non-Newly Diagnosed Type 2 Diabetes Mellitus in Primary Care: A Retrospective Cohort Study
por: An LW, et al.
Publicado: (2021)

Clinical implementetion of vildagliptin: data from recent studies comparing incretin-based medications
por: Elena Valer'evna Biryukova
Publicado: (2014)

New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin
por: Gallwitz B
Publicado: (2010)

Evaluation of glycaemic profile variability as a basis for insulin therapy strategy in pregnant women with type 1 diabetes
por: Alena V. Tiselko, et al.
Publicado: (2019)

First GLP-1 analog liraglutide: the result of clinical trails on efficacy
por: Alexander Sergeevich Ametov, et al.
Publicado: (2011)

Type 2 diabetes mellitus and the cardiometabolic syndrome: impact of incretin-based therapies
por: Schwartz S
Publicado: (2010)

New indications for exenatide therapy of type 2 diabetes mellitus
por: Olga Konstantinovna Vikulova, et al.
Publicado: (2010)

New prospects in the treatment of diabetes mellitus
por: Minara Shamkhalovna Shamkhalova, et al.
Publicado: (2012)

Ileal transposition in surgical treatment for type 2 diabetes mellitus
por: Oleg Viktorovich Kornyushin, et al.
Publicado: (2015)

Insulin degludec: a new basal insulin analogue with an ultra-long duration of action. Safety and efficacy in Russian patients with diabetes
por: Marina Vladimirovna Shestakova, et al.
Publicado: (2015)

The first and only combination of basal and prandial insulin analogs degludec and aspart: the position of Russian endocrinologists
por: M. V. Shestakova, et al.
Publicado: (2021)

Coping strategies in Type 1 and Type 2 diabetes patients using insulin: the relationship with emotional well-being and glycaemic control
por: Oleg G. Motovilin, et al.
Publicado: (2015)

A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives
por: Reed J, et al.
Publicado: (2021)

The role of human glucagon-like peptide-1 analog in therapy of type 2 dianetes mellitus
por: Marina Vladimirovna Shestakova
Publicado: (2010)

The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect
por: Enrique Z. Fisman, et al.
Publicado: (2021)

Vildagliptin and its role in the treatment of diabetes mellitus
por: Yury Shavkatovich Khalimov
Publicado: (2010)

Clinical Impact of Liraglutide as a Treatment of Obesity
por: Alruwaili H, et al.
Publicado: (2021)

Contrasting compositions of sitting, standing, stepping, and sleeping time: associations with glycaemic outcome by diabetes risk
por: Christian J. Brakenridge, et al.
Publicado: (2021)

The role of incretin-based therapies in the management of type 2 diabetes mellitus: perspectives on the past, present and future
por: Juris J. Meier
Publicado: (2019)

BH3-mimetics: recent developments in cancer therapy
por: Paul A. Townsend, et al.
Publicado: (2021)

Dual GIP–GLP1-Receptor Agonists In The Treatment Of Type 2 Diabetes: A Short Review On Emerging Data And Therapeutic Potential
por: Bastin M, et al.
Publicado: (2019)

The dynamics of invasive and noninvasive blood glucose monitoring methods: Recent trends
por: Alina Yur'evna Babenko, et al.
Publicado: (2016)

Critical appraisal of once-weekly formulation of exenatide in the control of type 2 diabetes mellitus
por: Seewoodhary J, et al.
Publicado: (2010)

Heart failure in diabetes: From an increased risk to a treatment target
por: Eberhard Standl
Publicado: (2018)

Heart failure outcomes in patients with type 2 diabetes mellitus: findings from the cardiovascular outcome trials of antidiabetes agents
por: Stefan D. Anker
Publicado: (2019)

The 5th International Conference on Advanced Technologies Treatments for Diabetes (ATTD 2012),2012 February 8-11, Barcelona (Spain)
por: Yury Ivanovich Filippov, et al.
Publicado: (2012)

Data on the first experience of insulin degludec (Tresiba®) treatment for type 2 diabetes in daily clinical practice
por: Lyudmila Alexandrovna Suplotova, et al.
Publicado: (2015)

The hermeneutical dimension of the bioethical enterprise. Notes on the dialogical/narrative foundations of bioethics
por: Lolas Stepke,Fernando
Publicado: (2018)

Efficacy and safety profile of once-weekly dulaglutide in type 2 diabetes: a report on the emerging new data
por: Kugler AJ, et al.
Publicado: (2018)

Psychosocial aspects of the usage of modern technologies in diabetes mellitus
por: Oleg G. Motovilin, et al.
Publicado: (2019)

Bioinspired Cellulase-Mimetic Solid Acid Catalysts for Cellulose Hydrolysis
por: Guangxu Yang, et al.
Publicado: (2021)

Dipeptidylpeptidase-4 inhibitors in the treatment of diabetes mellitus. Possibilities of cardioprotection
por: Elena Nikolaevna Trunina, et al.
Publicado: (2011)

Effectiveness prediction of Evogliptin treatment in type 2 diabetes mellitus in russian-korean population
por: Anna A. Mosikian, et al.
Publicado: (2018)

The relationships between glucose variability and renal function in type 2 diabetes patients on basal-bolus insulin therapy
por: Vadim V. Klimontov, et al.
Publicado: (2015)

Efficiency and safety of transfer of type 2 diabetes patients inadequately controlled on metformin alone to combined therapy with metformin and diabeton MB
por: Alexander Sergeevich Ametov, et al.
Publicado: (2009)

New glance at pathogenesis of type 2 diabetes mellitus: incretin and antiincretin systems.
por: Ekaterina Alekseevna Shestakova
Publicado: (2011)